

Edward S Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9888269/publications.pdf>

Version: 2024-02-01

32
papers

2,323
citations

394421

19
h-index

434195

31
g-index

35
all docs

35
docs citations

35
times ranked

2062
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, e26-e51.	5.6	521
2	Serum Amyloid A Regulates Granulomatous Inflammation in Sarcoidosis through Toll-like Receptor-2. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 360-373.	5.6	215
3	Sarcoidosis—scientific progress and clinical challenges. <i>Nature Reviews Rheumatology</i> , 2011, 7, 457-467.	8.0	213
4	Joint SNMMI—ASNC Expert Consensus Document on the Role of ¹⁸ F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1341-1353.	5.0	187
5	T Cell Responses to Mycobacterial Catalase-Peroxidase Profile a Pathogenic Antigen in Systemic Sarcoidosis. <i>Journal of Immunology</i> , 2008, 181, 8784-8796.	0.8	164
6	Etiology of Sarcoidosis. <i>Clinics in Chest Medicine</i> , 2008, 29, 365-377.	2.1	140
7	Joint SNMMI—ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. <i>Journal of Nuclear Cardiology</i> , 2017, 24, 1741-1758.	2.1	132
8	Etiologies of Sarcoidosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2015, 49, 6-18.	6.5	115
9	Genetic, Immunologic, and Environmental Basis of Sarcoidosis. <i>Annals of the American Thoracic Society</i> , 2017, 14, S429-S436.	3.2	87
10	The Pathogenesis of Pulmonary Sarcoidosis and Implications for Treatment. <i>Chest</i> , 2018, 153, 1432-1442.	0.8	80
11	Peripheral Blood Gene Expression as a Novel Genomic Biomarker in Complicated Sarcoidosis. <i>PLoS ONE</i> , 2012, 7, e44818.	2.5	73
12	Clinical and MRI phenotypes of sarcoidosis-associated myelopathy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	55
13	Myocardial Blood Flow and Inflammatory Cardiac Sarcoidosis. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 157-167.	5.3	41
14	Clinical and Imaging Response to Tumor Necrosis Factor Alpha Inhibitors in Treatment of Cardiac Sarcoidosis: A Multicenter Experience. <i>Journal of Cardiac Failure</i> , 2021, 27, 83-91.	1.7	32
15	The effect of community socioeconomic status on sepsis-attributable mortality. <i>Journal of Critical Care</i> , 2018, 46, 129-133.	2.2	31
16	Sarcoidosis-Related Cardiomyopathy: Current Knowledge, Challenges, and Future Perspectives State-of-the-Art Review. <i>Journal of Cardiac Failure</i> , 2022, 28, 113-132.	1.7	30
17	Transcriptomics of bronchoalveolar lavage cells identifies new molecular endotypes of sarcoidosis. <i>European Respiratory Journal</i> , 2021, 58, 2002950.	6.7	29
18	A Contemporary Analysis of Heart Transplantation and Bridge-to-Transplant Mechanical Circulatory Support Outcomes in Cardiac Sarcoidosis. <i>Journal of Cardiac Failure</i> , 2018, 24, 384-391.	1.7	27

#	ARTICLE	IF	CITATIONS
19	Innate immunity in sarcoidosis pathobiology. <i>Current Opinion in Pulmonary Medicine</i> , 2016, 22, 469-475.	2.6	22
20	Management of Cardiac Sarcoidosis Using Mycophenolate Mofetil as a Steroid-Sparing Agent. <i>Journal of Cardiac Failure</i> , 2021, 27, 1348-1358.	1.7	21
21	Association of Medication Adherence and Clinical Outcomes in Sarcoidosis. <i>Chest</i> , 2020, 158, 226-233.	0.8	18
22	Development and Implementation of an Alcohol Withdrawal Protocol using a 5-Item Scale, the Brief Alcohol Withdrawal Scale (BAWS). <i>Substance Abuse</i> , 2017, 38, 394-400.	2.3	16
23	Evaluating the Minimal Clinically Important Difference of the King's Sarcoidosis Questionnaire in a Multicenter Prospective Study. <i>Annals of the American Thoracic Society</i> , 2021, 18, 477-485.	3.2	16
24	Risk Factors for Infection and Health Impacts of the Coronavirus Disease 2019 (COVID-19) Pandemic in People With Autoimmune Diseases. <i>Clinical Infectious Diseases</i> , 2022, 74, 427-436.	5.8	15
25	Reassessing Th1 versus Th17.1 in sarcoidosis: new tricks for old dogma. <i>European Respiratory Journal</i> , 2018, 51, 1800010.	6.7	9
26	Cardiac sarcoidosis outcome differences: A comparison of patients with de novo cardiac versus known extracardiac sarcoidosis at presentation. <i>Respiratory Medicine</i> , 2022, 198, 106864.	2.9	8
27	Gene coexpression networks reveal novel molecular endotypes in alpha-1 antitrypsin deficiency. <i>Thorax</i> , 2021, 76, 134-143.	5.6	5
28	Defining CD4 T helper and T regulatory cell endotypes of progressive and remitting pulmonary sarcoidosis (BRITE): protocol for a US-based, multicentre, longitudinal observational bronchoscopy study. <i>BMJ Open</i> , 2021, 11, e056841.	1.9	4
29	Effect of Corticosteroids on Left Ventricular Function in Patients With Cardiac Sarcoidosis. <i>American Journal of Cardiology</i> , 2022, 177, 108-115.	1.6	4
30	Comparing Critical Care Admissions Among Urban Populations Before and During the COVID-19 Pandemic. <i>Health Security</i> , 2021, 19, S-34-S-40.	1.8	3
31	The association of baseline sarcoidosis measurements with 6-month outcomes that are of interest to patients: Results from the On-line Sarcoidosis Assessment Platform Study (OSAP). <i>Respiratory Medicine</i> , 2022, 196, 106819.	2.9	2
32	PH Professional Network: "Just Do It" Practical Aspects of Pulmonary Rehabilitation Programs. <i>Advances in Pulmonary Hypertension</i> , 2019, 18, 74-77.	0.1	0